课题基金 / 基金详情

VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics

VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics
VERITY:使用生物信息学和高级分析学的风湿病学价值和证据
批准号:
9413618
负责人:
Daniel Hal Solomon
金额:
$90.75万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-20 至 2022-08-31

项目摘要

项目成果

Daniel Hal Solomon的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT ABSTRACT Pediatric and adult rheumatic and musculoskeletal (MSK) diseases challenge the clinical researcher: they affect the population across the lifespan, impact a broad range of patient-centered outcomes, are rarely cured, and often have multiple possible treatment strategies. If properly addressed, these factors present tremendous opportunities for improving patient care and outcomes of patients. The overarching goal of the Brigham and Women’s Hospital (BWH) CCCR is to facilitate advancements in the methodologic sciences supporting clinical research within the NIAMS pediatric and adult rheumatic and musculoskeletal (MSK) disease missions. VERITY is organized around central scientific themes that can be applied to multiple rheumatic and MSK diseases. The Cores address the following cross-cutting areas: 1) including patients in clinical trial design, outcome selection, result interpretation, and dissemination; 2) integrating behavioral economics to enhance benefits of known interventions, i.e., adherence to medications, engagement in physical activity and weight loss; 3) extracting maximum information content from big data; 4) using smart technologies (mobile health) to advance clinical research; and 5) disseminating knowledge and mentoring of local and national rheumatic and MSK disease clinical researchers through distributed learning models. These scientific themes will be approached through several Cores described in the following Specific Aims. 1. To strategically direct, supervise, and provide financial accountability to VERITY and to train a broad group of local and national investigators for patient-oriented clinical research in pediatric and adult rheumatic and MSK diseases. (Administrative Core) 2. To develop and implement state of the art methods in innovative trials and longitudinal comparative effectiveness studies for rheumatic and MSK disease research. (Methodology Core) 3. To support bioinformatic approaches to enhance utilization of large databases for phenotyping relevant patients, and implementing biomarker, electronic medical record, and comparative effectiveness analyses. (Bioinformatics Resource Core)
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Rheumatoid Arthritis and the Risk of Cardiovascular Disease: Biomarkers Risk Prediction and Underlying Mechanisms
  • 批准号:
    10416473
  • 项目类别:
  • 资助金额:
    $68.32万
  • 财政年份:
    2022
  • 负责人:
    Daniel Hal Solomon
  • 依托单位:
Rheumatoid Arthritis and the Risk of Cardiovascular Disease: Biomarkers Risk Prediction and Underlying Mechanisms
  • 批准号:
    10643971
  • 项目类别:
  • 资助金额:
    $74.63万
  • 财政年份:
    2022
  • 负责人:
    Daniel Hal Solomon
  • 依托单位:
VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics
  • 批准号:
    9768189
  • 项目类别:
  • 资助金额:
    $89.49万
  • 财政年份:
    2017
  • 负责人:
    Daniel Hal Solomon
  • 依托单位:
VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics
  • 批准号:
    10017653
  • 项目类别:
  • 资助金额:
    $89.39万
  • 财政年份:
    2017
  • 负责人:
    Daniel Hal Solomon
  • 依托单位:
海外基金